These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 28228084)

  • 61. Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future.
    Kolyasnikova NM; Pestov NB; Sanchez-Pimentel JP; Barlev NA; Ishmukhametov AA
    Curr Pharm Biotechnol; 2023; 24(2):266-278. PubMed ID: 35578840
    [TBL] [Abstract][Full Text] [Related]  

  • 62. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells.
    Li Y; Li YF; Si CZ; Zhu YH; Jin Y; Zhu TT; Liu MY; Liu GY
    Virus Res; 2016 Jul; 220():172-8. PubMed ID: 27157859
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer.
    Haller SD; Monaco ML; Essani K
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33213031
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy.
    Choi JW; Kang E; Kwon OJ; Yun TJ; Park HK; Kim PH; Kim SW; Kim JH; Yun CO
    Gene Ther; 2013 Sep; 20(9):880-92. PubMed ID: 23514707
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
    Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
    Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters.
    Hasegawa N; Abei M; Yokoyama KK; Fukuda K; Seo E; Kawashima R; Nakano Y; Yamada T; Nakade K; Hamada H; Obata Y; Hyodo I
    Int J Cancer; 2013 Sep; 133(6):1479-88. PubMed ID: 23444104
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.
    Goradel NH; Mohajel N; Malekshahi ZV; Jahangiri S; Najafi M; Farhood B; Mortezaee K; Negahdari B; Arashkia A
    J Cell Physiol; 2019 Jun; 234(6):8636-8646. PubMed ID: 30515798
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model.
    Poutou J; Bunuales M; Gonzalez-Aparicio M; Garcia-Aragoncillo E; Quetglas JI; Casado R; Bravo-Perez C; Alzuguren P; Hernandez-Alcoceba R
    Gene Ther; 2015 Sep; 22(9):696-706. PubMed ID: 25938192
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
    Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
    Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy.
    Vragniau C; Hübner JM; Beidler P; Gil S; Saydaminova K; Lu ZZ; Yumul R; Wang H; Richter M; Sova P; Drescher C; Fender P; Lieber A
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077642
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus.
    Hashimoto M; Kuroda S; Kanaya N; Kadowaki D; Yoshida Y; Sakamoto M; Hamada Y; Sugimoto R; Yagi C; Ohtani T; Kumon K; Kakiuchi Y; Yasui K; Kikuchi S; Yoshida R; Tazawa H; Kagawa S; Yagi T; Urata Y; Fujiwara T
    Br J Cancer; 2024 Apr; 130(7):1187-1195. PubMed ID: 38316993
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Oncolytic virotherapy against the tumor microenvironment and its potential in pancreatic cancer.
    Zhang Y; Li Y; Chen K; Qian L; Wang P
    J Cancer Res Ther; 2022 Sep; 18(5):1247-1255. PubMed ID: 36204869
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model.
    Yoon AR; Kasala D; Li Y; Hong J; Lee W; Jung SJ; Yun CO
    J Control Release; 2016 Jun; 231():2-16. PubMed ID: 26951927
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.
    Zhang L; Hedjran F; Larson C; Perez GL; Reid T
    Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
    Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
    Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.
    Kwon OJ; Kang E; Kim S; Yun CO
    J Control Release; 2011 Oct; 155(2):317-25. PubMed ID: 21699929
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer.
    Xu C; Sun Y; Wang Y; Yan Y; Shi Z; Chen L; Lin H; Lü S; Zhu M; Su C; Li Z
    Cancer Lett; 2012 Jun; 319(2):154-163. PubMed ID: 22261331
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
    Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H
    Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.